Karl Storz Is Retiring a Surgical Robot That Worked

Karl Storz made a quiet decision this month that every founder building a better surgical robot should sit with. The company is keeping Asensus Surgical’s software, its clinical data, and its patents, folding all of it into its own R&D. And it is throwing the robot itself away. The Senhance system is being phased out, the Asensus brand retired, and 108 people in Morrisville, North Carolina, about 30 of them engineers, are losing their jobs. The hardware was not broken. That is the part worth slowing down for.

What Karl Storz is actually retiring

Karl Storz filed a layoff notice with North Carolina on June 16, according to MedTech Dive. The cuts begin August 15 and run over six months, landing on 108 of the more than 200 people Asensus employs across a dozen countries, including roughly 30 engineers and a layer of senior managers. The Senhance robot is being phased out, and development on the newer Luna platform is stopping. What survives is not the machine. Karl Storz is pulling Asensus’s software engineering, clinical data, and intellectual property into its global R&D group and running any future robotics under its own name. It bought Asensus back in August 2024. Most coverage frames this as an acquirer trimming a redundant product line, which is fair enough. It also skips the more useful question: why a working laparoscopic robot was worth more to Karl Storz dead than alive.

What actually kills a surgical robot

Surgeons and investors love to argue about whether a given robot gets better outcomes than a skilled surgeon operating by hand. In my experience that is the wrong argument. The da Vinci did not win because it beat the best laparoscopic surgeons. It won because it grew the number of surgeons who could perform a hard minimally invasive procedure at all, from a few dozen in the world to tens of thousands. More capable surgeons means more patients offered something other than open surgery. That is the win, and it has little to do with whether any one surgeon is sharper on the console.

Senhance never moved that number the way it had to. It put a second laparoscopic console in a room where the incumbent had already trained a generation of surgeons and locked in their muscle memory. Asking a surgeon to relearn a workflow is one of the hardest sells in medicine, and you only win it by handing back something big: a procedure they could not do before, or real friction taken out of one they already do. A comparable robot that asks for the same relearning without that payoff is not a cheaper da Vinci. It is a reason to stay with the da Vinci.

What this means if you are building hard tech

This is not only a surgical-robotics lesson, though it lands hardest there. Any founder putting a better version of an incumbent’s machine in front of a trained operator is making the same bet, whether that operator is a surgeon, a sonographer, a lab tech, or a line worker. The buyer is not measuring your device against the textbook ideal. They are measuring it against the workflow they already trust, and your improvement has to clear the cost of changing. Look at what Karl Storz actually kept: the engineers, the data, the patents. What it valued was the accumulated know-how, not the chassis around it. If your pitch is mostly that your hardware is better, you are competing on the part that turned out to be the easiest to walk away from.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →